Research Article

Molecular Hydrogen Inhibits Colorectal Cancer Growth via the AKT/SCD1 Signaling Pathway

Xiangyan Zhang,1,2,3 Geru Tao,2,3 Ya’nan Zhao,2,3 Sijie Xing,2,3 Jie Jiang,2,3 Boyan Liu,2,3 and Shucun Qin1,2,3

1Department of Pathophysiology, Basic Medicine College, Qingdao University, Qingdao 266000, China
2The Second Affiliated Hospital of Shandong First Medical University, Tai’an 271000, China
3Taishan Institute for Hydrogen Biomedicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Tai’an 271000, China

Correspondence should be addressed to Shucun Qin; 13583815481@163.com

Received 4 January 2022; Revised 9 April 2022; Accepted 12 April 2022; Published 26 April 2022

Copyright © 2022 Xiangyan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Molecular hydrogen (H2) has been considered a potential therapeutic target in many cancers. Therefore, we sought to assess the potential effect of H2 on colorectal cancer (CRC) in this study.

Methods. The effect of H2 on the proliferation and apoptosis of RKO, SW480, and HCT116 CRC cell lines was assayed by CCK-8, colony formation, and flow cytometry assays. The effect of H2 on tumor growth was observed in xenograft implantation models (inhalation of 67% hydrogen two hours per day). Western blot and immunohistochemistry analyses were performed to examine the expression of p-PI3K, PI3K, AKT, pAKT, and SCD1 in CRC cell lines and xenograft mouse models. The expression of SCD1 in 491 formalin-fixed, paraffin-embedded CRC specimens was investigated with immunohistochemistry. The relationship between SCD1 status and clinicopathological characteristics and outcomes was determined.

Results. Hydrogen treatment suppressed the proliferation of CRC cell lines independent of apoptosis, and the cell lines showed different responses to different doses of H2. Hydrogen also elicited a potent antitumor effect to reduce CRC tumor volume and weight in vivo. Western blot and IHC staining demonstrated that H2 inhibits CRC cell proliferation by decreasing pAKT/SCD1 levels, and the inhibition of cell proliferation induced by H2 was reversed by the AKT activator SC79. IHC showed that SCD1 expression was significantly higher in CRC tissues than in normal epithelial tissues (70.3% vs. 29.7%, \( p = 0.02 \)) and was correlated with a more advanced TNM stage (III vs. I + II; 75.9% vs. 66.3%, \( p = 0.02 \)), lymph node metastasis (with vs. without; 75.9% vs. 66.3%, \( p = 0.02 \)), and patients without a family history of CRC (78.7% vs. 62.1%, \( p = 0.047 \)).

Conclusion. This study demonstrates that high concentrations of H2 exert an inhibitory effect on CRC by inhibiting the pAKT/SCD1 pathway. Further studies are warranted for clinical evaluation of H2 as SCD1 inhibitor to target CRC.

1. Introduction

Colorectal cancer (CRC) is one of the most common cancers, and its morbidity has increased steadily in recent years [1]. The current treatment strategy is mainly based on surgery, chemotherapy, and targeted treatment, and the outcome of CRC patients has significantly improved due to anticancer therapy [2]. However, some patients have a high incidence of adverse effects caused by surgery and chemotherapy [3]. Therefore, it is important to explore new therapeutic strategies for CRC patients.

Molecular hydrogen (H2), which exerts antioxidant, anti-inflammatory, and antiapoptotic properties, has been implemented to treat various diseases, including inflammation [4], ischemia/reperfusion injury [5], atherosclerosis [6], and tumors [7]. Hydrogen molecules can directly diffuse
into the cytosol, mitochondria, and nucleus due to their permeability to cell membranes. Several intake methods, such as inhaling hydrogen, drinking hydrogen-rich water (HRW), and injecting hydrogen-saturated saline, are valid and reliable for treatment [7–9]. Reports have shown that \( H_2 \) can inhibit tumor cell proliferation, invasion, and migration via various molecular pathways. Wang et al. demonstrated that 60% \( H_2 \) could inhibit lung cancer migration and invasion by maintaining chromosome stability [10]. Yang et al. found that drinking HRW could inhibit endometrial cancer growth via ROS/NLRP3/caspase-1/GSDMD-mediated pyroptosis \textit{in vivo} [11]. A study from Japan showed that inhalation of \( H_2 \) for three h/day could improve the prognosis of advanced CRC patients by increasing the number of PD-L1/CD8+ cells [7]. Recently, Ma et al. argued that \( H_2 \) could regulate glioma stem-like cell differentiation and inhibit glucose metabolism in glioblastoma multiforme (GBM) tumors [12], which provides a new perspective on \( H_2 \) and tumor metabolism.

Metabolic pathways associated with oncogenesis and tumor metastasis have been explored in recent years, and targeting metabolism is a novel strategy for cancer treatment [13, 14]. Abnormal metabolic changes, including glucose uptake, glycolysis, and lactic acid production, are responsible for tumor growth, proliferation, and immune escape [13]. We previously observed that the HRW decreased serum oxidized low-density lipoprotein level and reduced ROS accumulation in the atherosclerosis model of \( Ldlr^{−/−} \) mice [15]. Moreover, hydrogen reduced the levels of lipid peroxidation (LOP) and increased the activity of superoxide dismutase (SOD) and free fatty acids [16]. These results strongly suggested that \( H_2 \) presents improved effects against lipoprotein metabolizer. Stearoyl-CoA desaturase 1 (SCD1) is the rate-limiting enzyme of fatty acid biosynthesis (FAS) that catalyzes the conversion of saturated fatty acids (SFAs) into monounsaturated fatty acids (MUFA)s, which are one of the critical components of triglycerides and membrane phospholipids. SCD1 have been found in many tumor tissues, including colorectal, gastric, breast, and lung cancer [17]. In addition, increased expression of SCD1 has been demonstrated to be correlated with cancer progression and poor prognosis in cancer patients [18, 19]. Moreover, SCD1 has been shown to be a marker of cancer stem cells (CSCs) in CRC [20]. An SCD1 inhibitor diminished the stemness of CSCs and reduced ovarian CSC proliferation \textit{in vivo} [21]. Thus, SCD1 appears to be a promising anticancer target. We previously observed that \( H_2 \) could reduce SCD1 expression in high-fat diet mediated liver injury rat model. This result prompts us to speculate that hydrogen could inhibit the proliferation of colorectal cancer cells by reducing the expression of SCD1. So, we conducted a study to explore the potential role of \( H_2 \) in the suppression of tumor proliferation of colorectal carcinoma cells.

Interestingly, we found that \( H_2 \) could inhibit colorectal carcinoma cell proliferation by downregulating the AKT/SCD1 pathway. Our study also revealed that SCD1 is highly expressed in CRC patients in eastern China. Therefore, \( H_2 \) may be a choice for CRC patients who harbor tumors with overexpression of SCD1.

2. Materials and Methods

2.1. Tissue Samples and Clinic Data. Four hundred ninety-one formalin-fixed, paraffin-embedded CRC specimens with matched adjacent normal epithelium tissues from CRC patients who underwent primary surgical resection from 2014 to 2016 in the Affiliated Hospital of Qingdao University were selected for this study. Patients who had undergone preoperative radiotherapy, chemotherapy, and/or targeted therapy were not included. The clinical and pathological variables were collected as previously described [22]. The patients were followed up until December 2020, and data concerning cancer recurrence and patient survival were collected. This study was approved by the Ethics Committee of the Shandong First Medical University and Shandong Academy of Medical Sciences (W202107060302) and the Affiliated Hospital of Qingdao University (QDFY-20130049).

2.2. Cell Lines and Cell Cultures. The human CRC cell lines RKO, SW480, and HCT116 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, C11995500BT, Thermo Fisher, USA) supplemented with 10%–30% fetal bovine serum (FBS; Gibco, 10099-141c, Thermo Fisher, USA), 100 IU penicillin, and 100 mg/mL streptomycin. All cells were incubated in a humidified atmosphere at 37°C with 5% CO2. For \( H_2 \) treatment (hydrogen machine; Wuxi Puhe, pH-1-A1 China), cells were cultured in 30% (30% \( H_2 \), 5% CO2, 21% O2, and 44% N2), 50% (50% \( H_2 \), 5% CO2, 21% O2, and 24% N2), or 70% \( H_2 \) (70% \( H_2 \), 5% CO2, 21% O2, and 4% N2), with 5% CO2 (5% CO2, 21% O2, and 74% N2) as the control conditions (Ctrl group). The AKT activator SC79 (HY-18749) was purchased from MedChemExpress (China).

2.3. Western Blot Analysis. Cells were lysed in RIPA buffer (CW2333S) supplemented with protease inhibitor cocktail (CW2200S) and phosphatase inhibitors (CW2338S). Total protein was extracted from tissue samples by a Tissue Protein Extraction Kit (CW0891M) (all from CWBIO, Beijing, China). Then, the protein concentration was determined using a BCA protein assay kit (Beyotime). Total proteins from cells (20 \( \mu \)g) and tissues (20 \( \mu \)g) were separated by SDS PAGE through a 10% gel and transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, IPVH00010, MA, USA) at 100 V for 60 min. After blocked with Tris-buffered saline containing Tween-20 (TBST, 1000:1) and 5% fat-free milk for 2 h, the membranes were incubated at 4°C overnight with primary antibodies against SCD1 (1:1000; Bioss, Cat# bs-3787R, Beijing, China), p-P3K (1:1000; Cat#: 17663; Cell Signaling Technology, Danvers, MA, USA), P3K (1:1000; clone: 1F6A7; Proteintech, Wuhan, China), phospho-AKT (Ser473; 1:1000; Cat#; 4069; Cell Signaling Technology, Danvers, MA, USA), AKT (1:1000; Cat#; 4691; Cell Signaling Technology), and actin (rabbit polyclonal; 1:2000; Cat#; E-AB-20058; Elabscience, Wuhan, China).

2.4. Cell Proliferation Assay. Cell proliferation was analyzed with a Cell Counting Kit-8 assay (Cat. CK04, Dojindo, Japan). Briefly, cells were seeded in 96-well plates at a
density of $1 \times 10^5$ cells per well and cultured for 5 days. The absorbance at 450 nm was measured in real-time every 24 h after incubation with 10 μL of CCK-8 reagent and 90 μL of cell culture medium for 2 h at 37°C. Light absorbance was measured by a microplate reader (Infinifit F200, Tecan, Australia). Experiments were performed independently at least 3 times.

2.5. Colony Formation Assay. For the colony formation assay, RKO, SW480, and HCT116 cells were seeded in 6-well plates at $1 \times 10^5$ cells per well and cultured for 14 days. The medium was replaced every 3 days. Cell colonies were washed twice with PBS, fixed with 4% paraformaldehyde for 30 min, and stained with 0.1% crystal violet for 1 min. The experiment was repeated at least 3 times.

2.6. Apoptosis Analysis. Cells were cultured in 6-well plates, washed twice with cold PBS, and treated with 0.25% trypsin digestion solution without EDTA (T1350, Solarbio, China). The cells were collected and resuspended in 500 μL of binding buffer (Cat. No. KGA107, KeyGEN BioTechnology, China). Then, 5 μL of Annexin V-FITC and 5 μL of propidium iodide were added to the buffer for staining for 10 min at room temperature. Cells were stained with PI and analyzed by flow cytometry (BD FACS Calibur).

2.7. Animal Experiments. A murine xenograft model was developed to investigate the effects of H2 on tumor proliferation in vivo. Four-week-old BALB/c- nude mice were purchased from Charles River (Beijing, China) and injected subcutaneously with $4 \times 10^6$ viable RKO cells. After injection, the mice were randomly assigned to 2 groups: the hydrogen inhalation group (66% H2 and 33% O2) and the control group (66% N2 and 33% O2) (hydrogen machine; Huimei, China). The mice in the inhalation group were exposed to H2 for 2 hours every day. Tumor growth was monitored by a linear monitor every 2 days. After 3 weeks, the tumors were removed, digested, and washed with cold PBS, and treated with 0.25% trypsin digestion solution without EDTA (T1350, Solarbio, China). Hematoxylin and eosin (H&E) staining were performed.

2.8. Immunohistochemistry. Paraffin-embedded tissues were deparaffinized and rehydrated with xylene and a graded ethanol series. Sections were treated with 3% hydrogen peroxide (10 min, room temperature), and antigen retrieval was performed with EDTA (pH = 8.0) for 10 min; the sections were then incubated with primary antibodies targeting p-p13K (1 : 600; Cat#: I7366; Cell Signaling Technology, Danvers, MA, USA), p-PI3K (1 : 600; clone: 1F6A7; Proteintech, Wuhan, China), SCD1 (1 : 400; Bioss, Cat# bs-3787R, Beijing, China), phospho-AKT (Ser473; 1 : 600; Cat# 4069; Cell Signaling Technology, Danvers, MA, USA), and AKT (1 : 400; Cat# 4691; Cell Signaling Technology) for 1 hour at 37°C followed by incubation with secondary antibody for 30 min at 37°C and rinses with PBS. Then, sections were developed with a 3,3-diaminobenzidine (DAB) kit (ZSGB-Bio, ZL1-9017, Beijing, China) and counterstained with hematoxylin.

All slides were examined and graded by two pathologists blinded to the clinical diagnosis. Cytoplasmic SCD1 was quantified based on the extent of positive tumor cells and the intensity the staining. The percentage of positively stained tumor cells was scored as 0 (negative), 1 (1–25%), 2 (26–50%), 3 (51–75%), and 4 (>75%). The two scores were multiplied, and the resulting immune-reactive score (IRS) (values from 0 to 12) was used to classify the samples into two categories: high (4–12) and low (1–3) [23].

2.9. Statistical Analysis. All data were evaluated using the SPSS 19.0.0 software (SPSS, Chicago, IL, USA) and expressed as the mean ± SD. All experiments were repeated at least 3 times. The relationship between the clinicopathological features and SCD1 expression, as well as the differences in SCD1 expression between normal epithelium and CRC tissues, was evaluated using a chi-square test or Fisher’s exact test. Survival analysis for disease-free survival (DFS) and overall survival (OS) was estimated using Kaplan–Meier analysis with the log-rank test. Multivariable analysis was performed using Cox regression. A probability (P) value < 0.05 was considered statistically significant.

3. Results

3.1. Hydrogen Inhibits CRC Cell Proliferation In Vitro in a Dose-Dependent Manner. To explore the potential effect of H2 on CRC, we evaluated the effect of different concentrations of H2 on the growth of RKO, SW480, and HCT116 cells. As shown in Figure 1(a), the proliferation results demonstrated that H2 had a potent inhibitory effect on SW480 cells, even at low concentrations (30%), while only high concentrations (more than 50%) of H2 suppressed RKO and HCT116 cells growth, as indicated by the CCK-8 assay (Figure 1(a)). There, we adopted 50% H2 for subsequent experiments. The CCK8 and colony formation assay showed that 50% H2 decreased the colony number of CRC cells (Figures 1(b) and 1(c)). To determine whether the inhibitory effect of H2 on cell proliferation is associated with apoptosis, we performed flow cytometry to explore the apoptosis after treatment with H2. Time-course analysis indicated that H2 did not promote apoptosis in CRC cells (Supplement Materials). These results demonstrate that H2 inhibits the proliferation of CRC cells in vitro in a dose-dependent manner.

3.2. Hydrogen Acts as a Tumor Suppressor of CRC In Vivo. Next, we evaluated the effect of H2 on CRC cell growth in a xenograft model. A total of 10 mice were injected with RKO cells. A transparent closed box (40 cm × 20 cm × 20 cm) connected to a hydrogen-oxygen nebulizer machine (Asclepius Meditec Inc., Shanghai, China) that produces an atmosphere containing 67% H2 and 33% O2 (V/V) was applied. Hydrogen treatment was administered from the second day after injection to the end of the experiment. Animals were placed in this box and inhaled the mixture for 2 h per day. During this time, the mice were awake and freely moving. A TRACE GC Ultra Gas Chromatograph (Thermo Fisher, MA, USA) was used to monitor the concentration of hydrogen gas in
the closed box. The control group was exposed to mixed air, which was composed of 67% N₂ and 33% O₂. According to our observations, the tumors were visible starting on day 7 after injection. The tumors exhibited irregularly exophytic, circumscribed, and cauliflower-like surface from day 7 onward. Mice were sacrificed, and the tumors were excised on day 21. As shown in Figure 2, tumor growth was significantly suppressed in nude mice that inhaled H₂. Hydrogen inhalation significantly reduced the tumor weight (1.11 ± 0.06 g vs. 1.56 ± 0.15 g, \( p = 0.021 \)) and volume.

**Figure 1:** Hydrogen inhibits CRC cell proliferation in vitro. As shown in (a), the proliferation results demonstrated that H₂ had a good inhibitory effect on SW480 cells, even at low concentrations (30%), while only high concentrations (more than 50%) of H₂ suppressed RKO and HCT116 cells growth, as determined by the CCK-8 assay. (b) 50% hydrogen decreased cell viability compared to the ctrl group in a time-dependent manner at 24, 48, 72, 96, and 120 h measured spectrophotometrically at 450 nm by CCK8 assay in RKO, SW480, and HCT116 cells. (c) The colony formation assay showed that 50% H₂ decreased the number of colonies arising from RKO, SW480, and HCT116 cells.
3.3. Hydrogen Inhibits CRC Cell Proliferation by Decreasing pAKT/SCD1. A previous study reported that SCD1, a lipogenesis-related gene in mammals, plays a pivotal role in tumor inhibition. To explore whether H₂ was involved in lipid metabolism in CRC, western blotting and IHC assays were performed to evaluate the status of SCD1 after H₂ treatment in CRC cells. We found that SCD1 was markedly downregulated in H₂ treatment CRC cells. The PI3K/AKT pathway controls various cellular activities, including proliferation, apoptosis, and autophagy. Therefore, we investigated the effect of H₂ on the PI3K/AKT signaling pathway in CRC cells. We found that H₂ obviously decreased the expression of phosphorylated AKT (pAKT) in three cell lines. Dramatically, the expression of PI3K was increased in RKO cell and decreased in SW480 and HCT116 cells (Figures 3(a) and 3(b)). To verify that H₂ inhibits the proliferation of colorectal cancer through PI3K/AKT pathway, we treated RKO, SW480, and HCT116 cells with SC79, an AKT activator that increased pAKT expression in a dose-dependent manner. As expected, the inhibition of cell proliferation induced by H₂ was reversed when all CRC cells were treated with SC79, as indicated in the CCK-8 assay (Figure 3(c)). Western blotting assays showed that the expressions of SCD1 and pAKT were significantly upregulated in a dose-dependent manner with SC79 treatment (Figure 3(c)). However, PI3K and p-PI3K showed different tendencies in these cells (Figure 3(b)). Together, these findings indicate that H₂ inhibits tumor growth both in vitro and in vivo by targeting the pAKT/SCD1 pathway.

3.4. SCD1 Status and Associations with Clinicopathological Characteristics and Prognostic Value in CRC Patients. IHC staining was performed to analyze the expression of SCD1 in paraffin-embedded CRC and normal epithelium tissues in 491 CRC patients. As shown in Figure 4(a), SCD1 expression levels in malignant tumors were significantly higher than those in normal epithelial tissues. High expression of SCD1 was observed in 70.3% (345/491) of tumor tissues, but only 29.7% (146/491) of the normal epithelial tissues exhibited high SCD1 expression (Table 1). Correlations between SCD1 status and clinicopathological characteristics, including age, sex, tumor location, tumor size, histological characteristics, TNM stage, and family history, were analyzed (Table 1). Elevated SCD1 expression was significantly correlated with more advanced TNM stage (III vs I + II: 75.9% vs. 66.3%, p = 0.02), lymph node metastasis (with vs. without: 75.9% vs. 66.3%, p = 0.02), and no family history of CRC (78.7% vs. 62.1%, p = 0.047). Although tumor with higher expressed SCD1 was present more often in patients with mucinous tumors (with vs. without), there was no significant difference in this study (86.9% vs. 71.7%, p > 0.05). No significant differences between SCD1 expression and other clinicopathological characteristics were found in the present study. In addition, univariable analysis with Kaplan-Meier survival curves indicated that the expression of SCD1 was not related to DFS and OS (Figure 5).
4. Discussion

In recent years, the role of the tumor microenvironment in the occurrence and development of cancer has been widely recognized. Tumor cells prefer a prooxidative microenvironment, as antioxidants prevent tumors from achieving their most ideal redox level; these antioxidants decrease telomerase activation, thereby inhibiting tumor cell viability [24]. The mechanism by which molecular hydrogen controls disease involves its antioxidant and anti-inflammatory properties to reduce oxidative stress [25]. Therefore, the antitumor effect of hydrogen may be related to the improvement of the tumor microenvironment, and the inhibitory activity of molecular hydrogen on cancer has been reported in several types of tumors, including lung cancer [10], endometrial cancer [11], glioblastoma [12], and colon cancer [7]. Moreover, both low concentrations and high concentrations of hydrogen presented significant antitumor effects [11, 12]. In the present study, we found that a low concentration of hydrogen (30%) could kill SW480 cells, but only a high

![Figure 3: Hydrogen inhibits CRC cell proliferation by decreasing pAKT/SCD1. (a) IHC assay in tumors (RKO cells) after H₂ treatment and control (100x). (b) Western blot analysis showing the expression levels of p-PI3K, PI3K, AKT, pAKT, and SCD1 in RKO, SW480, and HCT116 cells before and after H₂ treatment. Western blotting assays showed that the expression of SCD1 was significantly upregulated and presented a dose-dependent effect with SC79 treatment. (c) The inhibition of cell proliferation induced by H₂ was reversed when cells were treated with SC79, as determined by the CCK-8 assay.]

![Figure 4: The expression of SCD1 in paraffin-embedded CRC and normal epithelium tissues. SCD1 expression levels in malignant cells were significantly higher than those in normal epithelial tissues (100x).]

recognized.
Table 1: SCD1 status and its association with clinicopathological characteristics in CRC patients.

| Characteristics                        | Number | SCD1 expression | (%)  | Low   | (%)  | p     |
|----------------------------------------|--------|-----------------|------|-------|------|-------|
|                                         |        | High            |      |       |      |       |
| Gender                                 |        |                 |      |       |      |       |
| Male                                   | 299    | 203             | 67.90% | 96   | 32.10% | 0.15  |
| Female                                 | 192    | 142             | 73.90% | 50   | 26.10% |       |
| Age (years)                            |        |                 |      |       |      |       |
| ≤ 50                                   | 64     | 41              | 64.10% | 23 | 35.90% | 0.24  |
| >50                                    | 427    | 304             | 71.20% | 123 | 28.80% |       |
| Location                               |        |                 |      |       |      |       |
| Right side colon                       | 112    | 76              | 67.80% | 36 | 32.10% | 0.53  |
| Left side colon                        | 93     | 58              | 62.40% | 35 | 37.60% |       |
| Rectum                                 | 286    | 211             | 73.80% | 75 | 26.20% |       |
| Mucin production                       |        |                 |      |       |      |       |
| With                                   | 46     | 40              | 86.90% | 6   | 13.10% | 0.07  |
| Without                                | 425    | 305             | 71.76% | 120 | 28.20% |       |
| Tumor differentiation                  |        |                 |      |       |      |       |
| Poor                                   | 106    | 68              | 64.20% | 38 | 35.80% | 0.12  |
| Moderate/well                          | 385    | 277             | 71.90% | 108 | 28.10% |       |
| Tumor diameter                         |        |                 |      |       |      |       |
| ≤ 5 cm                                 | 269    | 190             | 70.60% | 79 | 29.40% | 0.85  |
| >5 cm                                  | 222    | 155             | 69.80% | 67 | 30.20% |       |
| Tumor stage                            |        |                 |      |       |      |       |
| I + II                                 | 288    | 191             | 66.30% | 97 | 33.70% | 0.02  |
| III                                    | 203    | 154             | 75.90% | 49 | 24.10% |       |
| Bowel wall invasion (T)                |        |                 |      |       |      |       |
| T1 + T2                                | 91     | 62              | 68.10% | 29 | 31.90% | 0.62  |
| T3 + T4                                | 400    | 283             | 70.80% | 117 | 29.20% |       |
| Lymph node metastasis (N)              |        |                 |      |       |      |       |
| Without                                | 288    | 191             | 66.30% | 97 | 33.70% | 0.02  |
| With                                   | 203    | 154             | 75.90% | 49 | 24.10% |       |
| Lymphovascular invasion                |        |                 |      |       |      |       |
| No                                     | 335    | 244             | 72.80% | 91 | 27.20% | 0.07  |
| Yes                                    | 156    | 101             | 64.70% | 55 | 35.30% |       |
| Alcohol intake                         |        |                 |      |       |      |       |
| Never                                  | 387    | 275             | 71.10% | 112 | 28.90% | 0.46  |
| Ever                                   | 104    | 70              | 67.30% | 34 | 32.70% |       |
| Smoking                                |        |                 |      |       |      |       |
| Ever                                   | 137    | 87              | 63.50% | 50 | 36.50% | 0.043 |
| Never                                  | 354    | 258             | 72.90% | 96 | 27.10% |       |
| Cancer family history                  |        |                 |      |       |      |       |
| Yes                                    | 93     | 68              | 73.10% | 25 | 26.90% | 0.25  |
| No                                     | 119    | 95              | 79.80% | 24 | 20.20% |       |
| Unknown                                | 279    |                 |      |       |      |       |
| Colorectal family history              |        |                 |      |       |      |       |
| Yes                                    | 29     | 18              | 62.10% | 11 | 37.90% | 0.047 |
| No                                     | 183    | 144             | 78.70% | 39 | 21.30% |       |
| Unknown                                | 279    |                 |      |       |      |       |
concentration of hydrogen (more than 50%) could inhibit RKO and HCT116 cell proliferation. SW480 and RKO cell lines are from different types of colon cancer: SW480 cells are derived from rectal cancer, and RKO cells are derived from colon adenocarcinoma. This indicates that different types of cells showed different responses to hydrogen based on the dose. Therefore, the appropriate concentration of hydrogen in cancer treatment needs to be verified by additional and more rigorous clinical studies. In addition, we observed that hydrogen did not promote apoptosis in CRC cells. Further investigation is still needed to ascertain the molecular mechanisms involved in the hydrogen-mediated control of proliferation in CRC cells.

With the development of related studies in hydrogen biomedicine, the traditional anti-inflammatory and antioxidant mechanisms are not enough to explain the inhibitory effects of hydrogen on cancer. Recently, Liu et al. [12] demonstrated that hydrogen can act on biological enzymes and promote acetylcholinesterase activity, thus reducing the production of toxic free radicals and inducing glioma cells to dedifferentiate into glial stem cells. Interestingly, the physical effect of hydrogen on CRC tumor stem cell differentiation remains largely unknown.

In mammalian cells, SCD1 is responsible for de novo synthesis of FAs, which are vital constituents in cellular processes, such as components of biological membranes and sources of energy and cell lipids (i.e., phospholipids, diacylglycerols, triacylglycerols, and cholesteryl esters). SCD1 expression is significantly elevated in various human cancer cells, including liver cancer [18], breast cancer [19], and colon cancer [26]. Moreover, the increased expression of SCD1 is positively correlated with cancer aggressiveness and poor patient prognosis [18, 19]. SCD1 has been identified as a novel key player in tumorigenesis and a potential target for anticancer therapy. The proposed underlying mechanisms of SCD1 in cancer involve multiple aspects: (a) inhibiting cell survival and proliferation by regulating lipid metabolism; (b) influencing the physiologic processes of cell cycle progression, apoptosis, and cell contact inhibition; and (c) promoting cancer stem cell (CSC) transformation [20]. A study conducted by Scaglia and Igal [27] demonstrated that knockdown of SCD1 in human lung cancer cells can decrease the rate of cell proliferation and induce apoptosis by decreasing MUFA and phospholipid synthesis. A recent analysis revealed that the SCD1-dependent regulation of FA, TAG, cholesterol, and PL synthesis was dependent on SREBP activation [28]. Yu et al. [26] found that SCD1 could induce CSC-specific apoptosis in colon cancer by targeting suppressed Notch and Wnt signaling pathways. These observations provided strong evidence that SCD1 is a crucial driver of neoplastic progression, and the application of SCD1 inhibitors may be an effective anticancer strategy. Additionally, a previous study provided evidence for the involvement of SCD1 in AKT phosphorylation. Scaglia and Igal [29] demonstrated that knockdown of SCD1 impaired lung cancer cells via inhibition of AKT phosphorylation. Holder et al. [30] showed that the expression of SCD1 is upregulated by PI3K/AKT signaling in breast cancer.

| Characteristics | Number | SCD1 expression (%) | Low (%) | p  |
|-----------------|--------|---------------------|---------|----|
| MSI status      |        |                     |         |    |
| MSI             | 68     | 46                  | 67.60%  | 22 |
| MSS             | 423    | 299                 | 70.70%  | 124| 0.61|
| KRAS status     |        |                     |         |    |
| Mutation        | 212    | 147                 | 69.30%  | 65 |
| Wild type       | 279    | 198                 | 70.90%  | 81 |

Figure 5: The prognostic value of SCD1 expression in primary CRC. Survival curves for disease free survival (DFS) and overall survival (OS) in stages I–III colorectal cancer according to SCD1 status: (a) DFS according to SCD1; (b) OS according to SCD1.
In the present study, we explored the effects of hydrogen on CRC and provided the first evidence that hydrogen inhibits CRC cell proliferation via the pAKT/SCD1 pathway. We demonstrated that inhalation of 67% hydrogen gas reduced the volume and weight of CRC tumors in a xenograft mouse model. Our study suggests that inhalation of hydrogen is effective in treating CRC. Tumor tissue sections in the hydrogen group presented much less pAKT and SCD1 staining by IHC, and SCD1 expression was higher in CRC than in adjacent normal tissues. However, there are some limitations to our study. First, current knowledge demonstrates that SCD1 inhibits CRC proliferation by promoting apoptosis, mitochondrial dysfunction, ceramide synthesis, and stem cell differentiation [26, 28, 40], but we did not test the mechanism downstream of SCD1 in hydrogen-treated CRC cells. Second, we did not use the patient tissue-derived tumor xenografts, which were considered to be more accurately mimic human tumors with the high similarity in the tumor growth environment, so the effect of hydrogen in the orthotopic colorectal cancer model needs be further studied. Last, we did not determine the in vitro \( \text{H}_2 \) concentration of the medium equivalent to the \( \text{H}_2 \) concentration of the inhalation treatment used in vivo, so the \( \text{H}_2 \) concentrations in vitro and in vivo may not have been equivalent.

5. Conclusion

The present study demonstrated that a high concentration of hydrogen exerts an inhibitory effect on CRC by inhibiting the pAKT/SCD1 pathway. SCD1 expression levels in malignant tissues were significantly higher than those in matched normal epithelial tissues in patients with CRC. Further studies are warranted for the clinical evaluation of hydrogen as an SCD1 inhibitor to target CRC.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

This study was approved by the Ethics Committee of the Shandong First Medical University and Shandong Academy of Medical Sciences (W202107060302) and the Affiliated Hospital of Qingdao University (QDFY-20130049).

Consent

All patients/guardians had signed informed consent.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

All the authors read and approved the final manuscript. Xiangyan Zhang and Geru Tao contributed equally to this work.

Acknowledgments

We thank Peng Jiao for her generous help with the flow cytometer experiment. This work is supported by the Academic Promotion Program of Shandong First Medical University (2019QL010, 2019PT009) and the National Natural Science Foundation of China (81770855).

Supplementary Materials

H₂ did not promote apoptosis for CRC cells. (Supplementary Materials)

References

[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA: a Cancer Journal for Clinicians, vol. 69, no. 1, pp. 7–34, 2019.
[2] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[3] N. C. Turner and J. S. Reis-Filho, “Genetic heterogeneity and cancer drug resistance,” Lancet Oncology, vol. 13, no. 4, pp. e178–e185.
[4] Y. Wu, M. Yuan, J. Song, X. Chen, and H. Yang, “Hydrogen gas from inflammation treatment to cancer therapy,” ACS Nano, vol. 13, no. 8, pp. 8505–8511, 2019.
[5] R. Zou, M. H. Wang, Y. Chen et al., “Hydrogen-rich saline attenuates acute lung injury induced by limb ischemia/reperfusion via down-regulating chemerin and NLRP3 in rats,” Shock (Augusta, Ga.), vol. 52, no. 1, pp. 134–141, 2019.
[6] G. Song, M. Li, H. Sang et al., “Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome,” Journal of Lipid Research, vol. 54, no. 7, pp. 1884–1893, 2013.
[7] J. Akagi and H. Baba, “Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis,” Oncology Reports, vol. 41, no. 1, pp. 301–311, 2019.
[8] K. Uto, S. Sakamoto, W. Que et al., “Hydrogen-rich solution attenuates cold ischemia-reperfusion injury in rat liver transplantation,” BMC Gastroenterology, vol. 19, no. 1, pp. 25–34, 2019.
[9] G. Tao, G. Song, and S. Qin, “Molecular hydrogen: current knowledge on mechanism in alleviating free radical damage and diseases,” Acta Biochimica et Biophysica Sinica, vol. 51, no. 12, pp. 1189–1197, 2019.
[10] D. Wang, L. Wang, Y. Zhang, Y. Zhao, and G. Chen, “Hydrogen gas inhibits lung cancer progression through targeting SMC3,” Biomedicine & pharmacotherapy = Biomedecine & pharmacothérapie, vol. 104, pp. 788–797, 2018.
[11] Y. Yang, P. Y. Liu, W. Bao, S. J. Chen, F. S. Wu, and P. Y. Zhu, “Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway,” BMC Cancer, vol. 20, no. 1, pp. 28–46, 2020.
[12] M. Liu, F. Xie, Y. Zhang et al., “Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation,” Stem Cell Research & Therapy, vol. 10, no. 1, pp. 145–154, 2019.
[13] N. Hay, “Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?,” Nature Reviews. Cancer, vol. 16, no. 10, pp. 635–649, 2016.
[14] D. Huang, L. Cc, and Z. Hf, “Hyposia and cancer cell metabolism,” Acta Biochimica et Biophysica Sinica Shanghai, vol. 46, no. 3, pp. 214–219, 2014.
[15] G. Song, C. Zong, Z. Zhang et al., “Molecular hydrogen stabilizes atherosclerotic plaque in low-density lipoprotein receptor-knockout mice,” Free Radical Biology & Medicine, vol. 87, pp. 58–68, 2015.
[16] B. Liu, Y. Xie, J. Chen et al., “Protective effect of molecular hydrogen following different routes of administration on D-galactose-induced aging mice,” Journal of Inflammation Research, vol. Volume 14, pp. 5541–5550, 2021.
[17] S. Guo, Y. Wang, D. Zhou, and Z. Li, “Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging,” Scientific Reports, vol. 4, no. 1, pp. 5959–5967, 2015.
[18] A. Budhu, S. Roessler, X. Zhao et al., “Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes,” Gastroenterology, vol. 144, no. 5, pp. 1066–1075.e1, 2013.
[19] A. Holder, A. Gonzalez-Angulo, H. Chen et al., “High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients,” Breast Cancer Research and Treatment, vol. 137, no. 1, pp. 319–327, 2013.
[20] Z. Traczyk-Gaszewksa and P. Dobrzyński, “Stearoyl-CoA desaturase 1 as a therapeutic target for the treatment of cancer,” Cancers, vol. 11, no. 7, pp. 948–972, 2019.
[21] J. Li, S. Condello, J. Thomes-Pepin et al., “Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells,” Cell Stem Cell, vol. 20, no. 3, pp. 303–314.e5, 2017.
[22] X. Zhang, W. Ran, J. Wu et al., “Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective
study in Eastern China,” PeerJ, vol. 6, no. 2, p. e4341-e 4365, 2018.

[23] Y. Luo, L. Wang, W. Ran et al., “Overexpression of SAPCD2 correlates with proliferation and invasion of colorectal carcinoma cells,” Cancer Cell International, vol. 20, no. 1, pp. 43–51, 2020.

[24] P. Li, M. Wu, J. Wang, Y. Sui, S. Liu, and D. Shi, “NAC selectively inhibit cancer telomerase activity: a higher redox homeostasis threshold exists in cancer cells,” Redox Biology, vol. 8, pp. 91–97, 2016.

[25] J. Y. Zhang, C. Liu, L. Zhou et al., “A review of hydrogen as a new medical therapy,” Hepato-Gastroenterology, vol. 59, no. 116, pp. 1026–1032, 2012.

[26] Y. Yu, H. Kim, S. Choi et al., “Targeting a lipid desaturation enzyme, SCD1, selectively eliminates colon cancer stem cells through the suppression of Wnt and NOTCH signaling,” Cell, vol. 10, no. 1, pp. 106–119, 2021.

[27] N. Scaglia and R. Igal, “Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells,” The Journal of biological chemistry., vol. 280, no. 27, pp. 25339–25349, 2005.

[28] X. Y. Qin and S. Kojima, “Inhibition of Stearoyl-CoA desaturase-1 activity suppressed SREBP signaling in colon cancer cells and their spheroid growth,” Gastrointestinal Disorders, vol. 1, pp. 191–200, 2019.

[29] N. Scaglia and R. Igal, “Inhibition of Stearoyl-CoA desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis,” International Journal of Oncology, vol. 33, no. 4, pp. 839–850, 2008.

[30] D. Luyimbazi, A. Akcakanat, P. McAuliffe et al., “Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer,” Molecular Cancer Therapeutics, vol. 9, no. 10, pp. 2770–2784, 2010.

[31] S. Revathidevi and A. Munirajan, “Akt in cancer: mediator and more,” Seminars in Cancer Biology, vol. 59, pp. 80–91, 2019.

[32] M. Song, A. Bode, Z. Dong, and M. H. Lee, “AKT as a therapeutic target for cancer,” Cancer Research, vol. 79, no. 6, pp. 1019–1031, 2019.

[33] O. Chen, Z. Cao, H. Li et al., “High-concentration hydrogen protects mouse heart against ischemia/reperfusion injury through activation of thePI3K/Akt1 pathway,” Scientific Reports, vol. 7, no. 1, pp. 14871–14884, 2017.

[34] P. Vidossich, G. Fiorin, M. Alfonso-Prieto, E. Derat, S. Shaik, and C. Rovira, “On the role of water in peroxidase catalysis: a theoretical investigation of HRP compound I formation,” The journal of physical chemistry B, vol. 114, no. 15, pp. 5161–5169, 2010.

[35] G. Chreiff, E. Baxter, T. Doukov et al., “Crystal structure of the pristine peroxidase ferryl center and its relevance to proton-coupled electron transfer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 5, pp. 1226–1231, 2016.

[36] Y. Niu, Q. Nie, L. Dong et al., “Hydrogen attenuates allergic inflammation by reversing energy metabolic pathway switch,” Scientific Reports, vol. 10, no. 1, pp. 1962–1974, 2020.

[37] T. Wang, L. Zhao, M. Liu et al., “Oral intake of hydrogen-rich water ameliorated chlorpyrifos-induced neurotoxicity in rats,” Toxicology and Applied Pharmacology, vol. 280, no. 1, pp. 169–176, 2014.

[38] G. Owen, S. Stoychev, I. Achilonu, and H. W. Dirr, “Phosphorylation- and nucleotide-binding-induced changes to the stabil-